Forian’s (FORA) “Buy” Rating Reaffirmed at Roth Mkm

Roth Mkm restated their buy rating on shares of Forian (NASDAQ:FORA) in a research note published on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock.

Forian Stock Down 1.5 %

Shares of FORA stock opened at $2.00 on Thursday. Forian has a 12-month low of $1.99 and a 12-month high of $4.15. The company has a market capitalization of $62.22 million, a PE ratio of -22.22 and a beta of 1.09. The firm has a 50 day moving average price of $2.13 and a two-hundred day moving average price of $2.43.

Institutional Trading of Forian

Institutional investors and hedge funds have recently modified their holdings of the business. Caprock Group LLC acquired a new position in Forian during the second quarter worth about $230,000. Canton Hathaway LLC boosted its stake in shares of Forian by 2.3% in the 3rd quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock valued at $582,000 after purchasing an additional 6,125 shares in the last quarter. Finally, Elser Financial Planning Inc bought a new stake in shares of Forian during the 2nd quarter valued at approximately $1,885,000. 19.25% of the stock is currently owned by institutional investors.

Forian Company Profile

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.